Skip to content
Pipeline

Therapeutic Candidates

Cardiometabolic and Obesity 

 

We are expanding our preclinical pipeline with high-value therapeutic candidates for obesity and other cardiometabolic diseases.  Our portfolio of next-generation cardiometabolic and obesity drugs aims to overcome the challenges of current anti-obesity medications by preserving and building muscle mass during weight loss, preventing weight re-gain, and treating cardiovascular disease related to metabolic syndrome. We see the potential for new drugs complementing currently approved Glucagon-type peptide-1 (GLP-1) agonists to promote quality weight loss with patient benefits such as fewer side effects and less frequent dosing.  

 

Therapeutic Area
Programs
Early Discovery E Disc
Late Discovery L Disc
Lead Optimization L Opt
IND-Enabling IND
Partner Prt
Therapeutic Area: Cardiometabolic
Programs: IBIO-600

Myostatin

Myostatin is a protein in the transforming growth factor beta (TGFb) superfamily that plays an important role in metabolism and muscle growth; it can slow or stop muscle growth when activated. We’re investigating myostatin inhibitors that could block myostatin activity to potentially promote muscle growth and improve metabolic health.

Programs: Myostatin x Activin A

This bi-specific antibody is designed to block the activity of the proteins Myostatin and Activin A to potentially enhance muscle growth and improve quality weight loss, along with, or after treatment with incretin-class therapeutics. It’s being developed for obesity and other cardiometabolic disorders. Myostatin and Activin A inhibition are also key features for treating PH-HFpEF.

Programs: Activin E
Obesity
Programs: Target 3
Obesity
Programs: Target 4
Obesity

Immuno-Oncology

 

Beyond cardiometabolic disease, we have a pre-clinical pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor. 

 

Therapeutic Area
Programs
Early Discovery Disc
Late Discovery L Disc
Lead Optimization L Opt
IND-Enabling IND
Therapeutic Area: Oncology
Programs: IBIO-101†

This IL-2-sparing anti-CD25 antibody aims to reduce tumor growth by selectively depleting immunosuppressive regulatory T cells without affecting cancer-killing effector T cells. It’s being investigated as a fast follower to Hoffman-La Roche’s RG6292 molecule, with potential indications including solid tumors, hairy cell leukemia, relapsed multiple myeloma, lymphoma, and head and neck cancers.

Learn More

Programs: CCR8†

This potential candidate is designed to selectively bind to CCR8, a protein highly expressed by regulatory T cells in the tumor microenvironment, without killing its closely related neighbor, CCR4. When CCR8 and regulatory T cells are depleted without killing CCR4, CCR4 triggers an innate immune response to selectively target and kill tumors. This target can potentially treat a broad range of solid tumor cancers, alone and in combination with checkpoint inhibitors.

Learn More

Programs: Trop 2 x CD3*†

TROP-2 (Trophoblast cell-surface antigen 2) is an overexpressed cell surface protein in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers. It plays a crucial role in promoting tumor growth, survival, and metastasis by regulating cell signaling pathways, adhesion, and epithelial-mesenchymal transition. Targeting TROP-2 with bispecific antibodies aims to engage the immune system to treat TROP-2-positive cancers selectively and effectively.  TROP-2 can potentially treat cancers of the head and neck, lung, ovary, breast, and pancreas.

Learn More

Programs: MUC 16 x CD3*†

MUC16 is a tumor-associated epitope that is over-expressed and shed by tumor cells, making it difficult to kill the tumor. The antibody being investigated binds to nearby epitopes that are not shed to maintain activity against the tumor. This target can potentially treat ovarian, uterine, and pancreatic cancers.

Learn More

Programs: EGFRvIII†

This anti-EGFRvIII antibody is being investigated to treat glioblastoma and other cancers by selectively killing EGFRvIII tumor cells without destroying healthy tissue. The novel antibody has high antibody-dependent cellular cytotoxicity (ADCC), potentially reducing toxicity and expanding the therapeutic window. Potential indications include glioblastoma, head and neck cancer, and non-small cell lung cancer.

Learn More

Programs: Target 5
Solid Tumors

* Developed with EngageTxTM bispecific platform and ShieldTx® masking technology
† Patent pending

IBio’s rapidly expanding pipeline is driven by the company’s antibody discovery platform, a fully integrated technology stack powered by machine learning to deliver next-generation precision antibodies for difficult targets and modes of action with the potential for high developability and enhanced safety.  

We are excited about the potential therapeutic benefits of our proprietary pipeline and are looking for partners who share our passion for bringing innovative treatments to advance healthcare and improve patient lives. 

To learn more about our pipeline candidates and potential partnership opportunities, please contact us. 

Top